Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.

@article{Lee2009ComparisonOG,
  title={Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.},
  author={S M Lee and Lindsay E. James and W Qian and Shelly Spiro and Tim Eisen and Nicole H Gower and David Raymond Ferry and David Gilligan and Peter G. Harper and Joseph Prendiville and Marc Hocking and Robin Michael Rudd},
  journal={Thorax},
  year={2009},
  volume={64 1},
  pages={75-80}
}
BACKGROUND The combination of cisplatin and etoposide (PE) has been a standard treatment for patients with poor-prognosis small cell lung cancer (SCLC). This non-inferiority design trial aimed to determine whether the combination of gemcitabine and carboplatin (GC) results in similar survival but is less toxic with better quality of life. METHODS Previously untreated patients with SCLC with extensive disease or limited stage with poor prognostic factors were randomly assigned to six 3-weekly… CONTINUE READING
16 Citations
32 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Results of a phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell

  • VP Israel, K Chansky, D Gandara
  • lung cancer
  • 2004

untreated, extensive-stage small cell lung cancer

  • A Sandler, C Langer, PA Bunn
  • J Clin Oncol 2006;24:2038-43
  • 2003

Similar Papers

Loading similar papers…